• Gemcitabine: Applied Protocols and Innovations for Cancer Re

  2026-05-05

  Gemcitabine, a DNA synthesis inhibitor with robust anti-tumor activity, remains essential for dissecting DNA damage and apoptosis pathways. This article delivers workflow-optimized guidance, troubleshooting tips, and translational insights based on the latest experimental and omics-driven breakthroughs—empowering precise, reproducible use in advanced cancer models.

• Irinotecan (CPT-11): Applied Workflows and Troubleshooting i

  2026-05-04

  Irinotecan (CPT-11) is a cornerstone compound for modeling DNA damage and therapeutic efficacy in colorectal cancer research. This guide delivers actionable, data-backed workflows and advanced troubleshooting tips to maximize reproducibility and translational impact using Irinotecan from APExBIO.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guide for Labeling

  2026-05-04

  Cy3 NHS ester (non-sulfonated) is a robust fluorescent dye for labeling amino groups in proteins, peptides, and oligonucleotides. It addresses the need for high-sensitivity detection in biomedical imaging but should not be used when a water-soluble reagent is required for fragile protein systems.

• Sisomicin: Translational Leverage for Infection Model Innova

  2026-05-03

  This thought-leadership article analyzes the mechanistic and translational strengths of Sisomicin, a broad-spectrum aminoglycoside antibiotic, for infection model research. It guides researchers through mechanistic insight, protocol optimization, resistance challenges, and comparative context, providing actionable strategies to maximize experimental and clinical impact.

• Kanamycin Sulfate: Water-Soluble Antibiotic for Research Use

  2026-05-02

  Kanamycin Sulfate is a high-purity, water-soluble antibiotic used in microbiology and antibiotic resistance research. It selectively inhibits bacterial protein synthesis and is validated for cell culture selection workflows. APExBIO provides Kanamycin Sulfate (SKU A2516) with 98% purity and robust quality control.

• Vincristine Sulfate in Cancer Research: Applied Workflows &

  2026-05-01

  Vincristine sulfate is a gold-standard microtubule disrupter that enables reproducible, mechanism-driven cancer research. This guide delivers experimental workflow enhancements, troubleshooting strategies, and evidence-backed applications using APExBIO’s Vincristine sulfate (A1765) for high-impact oncology studies.

• Risedronate Sodium: FPPS Inhibitor for Bone and Lung Researc

  2026-05-01

  Risedronate Sodium is a validated farnesyl pyrophosphate synthase (FPPS) inhibitor with proven efficacy in inhibiting osteoclast-mediated bone resorption and emerging applications in emphysema models. Its synergy with vitamin D₃ and enhanced delivery via nanoformulations position it as a cornerstone in bone metabolism research.

• Sulfaphenazole: Bridging CYP2C9 Inhibition and Endothelial H

  2026-04-30

  Explore how Sulfaphenazole, a potent CYP2C9 inhibitor, restores vascular endothelial function in diabetes through oxidative stress reduction. Gain unique insights into protocol design and translational applications, setting this article apart from previous coverage.

• mTORC1-IRE1a Axis Drives Palmitate Lipotoxicity in Hepatocyt

  2026-04-30

  This study demonstrates that palmitate-induced lipotoxicity in hepatocytes is driven by activation of the mTORC1-IRE1a pathway, leading to increased triglyceride secretion and cell death. These findings clarify cellular mechanisms underlying saturated fatty acid toxicity and suggest new targets for metabolic disease intervention.

• Optimizing Cell Proliferation Assays with Murine Recombinant

  2026-04-29

  Murine recombinant PDGF-BB unlocks high-fidelity, reproducible stimulation of smooth muscle and connective tissue cell proliferation, bridging metabolic research with robust assay design. This article distills advanced workflows, troubleshooting insights, and translational strategies for harnessing PDGF-BB’s mitogenic power in pulmonary vascular remodeling studies.

• Co-Targeting BRD4 and RAC1 Disrupts c-MYC Axis in Breast Can

  2026-04-29

  This study demonstrates that simultaneous inhibition of BET bromodomain BRD4 and RAC1 suppresses growth, stemness, and tumorigenic potential in multiple breast cancer subtypes. Mechanistically, the combined approach disrupts the oncogenic c-MYC-G9a-FTH1 pathway and downregulates HDAC1, offering a compelling rationale for exploring co-targeted epigenetic therapies.

• Neurogenetic Gradients of Nurr1+ Neurons in Rat Claustrum De

  2026-04-28

  Fang et al. (2021) systematically charted the developmental patterning and neurogenetic gradients of Nurr1-positive neurons in the rat claustrum and lateral cortex, resolving previous controversies regarding their temporal and spatial origins. Their integration of EdU birth dating with in situ hybridization provides critical insight into the sequential generation of distinct claustral and cortical neuron populations, with implications for understanding forebrain organization.

• SU6656 Src Inhibitor: Bridging Platelet Biotech and Radiothe

  2026-04-28

  This thought-leadership article offers translational researchers a mechanistic and strategic roadmap for leveraging SU6656—a selective Src tyrosine kinases inhibitor—in both ex vivo platelet generation and as a radiotherapy sensitizer. Anchored in recent stem cell and oncology advances, the article explores how modulation of Src signaling can empower scalable cell therapy manufacturing and potentiate anti-cancer interventions. Drawing on validated protocol parameters and real-world evidence, the piece distinguishes itself by synthesizing insights across regenerative medicine and tumor biology, while providing actionable guidance for experimental design.

• Ordered DNA Frameworks Advance Enzymatic Oligonucleotide Syn

  2026-04-27

  This study introduces a tetrahedral DNA nanostructure (TDN) interface that greatly improves enzymatic oligonucleotide synthesis (EOS) by enhancing enzyme accessibility and catalytic efficiency. The innovation reduces deletion errors and increases yield, with direct implications for DNA data storage and advanced genetic research.

• SU6656 Src Inhibition: Bridging Cancer Research & Platelet B

  2026-04-27

  Explore the dual translational potential of SU6656, a potent Src tyrosine kinases inhibitor: from enhancing radiotherapy in oncology to enabling scalable ex vivo platelet production from hiPSCs. This article synthesizes mechanistic insights, protocol guidance, and a forward-looking outlook for translational researchers seeking robust, cost-effective, and clinically relevant solutions.

16340 records 1/1090 page Next 12345 下5页 Last page